Bharat Immunological & Biological Corporation Ltd (BIBCL) is currently trading at 16.93 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit specializing in vaccines and pharmaceutical products, under the Department of Biotechnology. The company manufactures Oral Polio Vaccine (OPV), Zinc Tablets, and diarrhea management kits, and has diversified into plasma-derived medicines and oral cholera vaccine. BIBCOL's production facility, located in Bulandshahr, has capacity to produce 100 million units of OPV, demonstrating its significant operational scale. It is strategically positioned with long-term supply agreements with the Government of India for its OPV, contributing to national immunization programs. Local R&D efforts include developing a hepatitis B vaccine, showcasing BIBCOL's commitment to innovation and expanding product offerings.

Over the past 52 weeks, Bharat Immunological & Biological Corporation Ltd has traded between a low of ₹15.80 and a high of ₹28.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bharat Immunological & Biological Corporation Ltd has a market capitalization of approximately 73.10. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bharat Immunological & Biological Corporation Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -4.05 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 73.10 Cr, Bharat Immunological & Biological Corporation Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bharat Immunological & Biological Corporation Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bharat Immunological & Biological Corporation Ltd is -4.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.